Ondine Biomedical Begins US Phase 3 Clinical Trial

Ondine Biomedical Inc., a Canadian company specializing in light-activated antimicrobial treatments, has announced the start of the LANTERN Phase 3 clinical trial. This trial focuses on their nasal photodisinfection technology, Steriwave®, and has received the go-ahead from the U.S. FDA. The trial preparation includes 14 hospital sites and aims to enroll 5,000 surgical patients in collaboration with HCA Healthcare.

The trial will compare infection prevention practices with and without Ondine's technology, which is a 5-minute, non-invasive procedure. This method decolonizes the nose, fighting pathogens without antibiotics, thus addressing antimicrobial resistance concerns.